A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: Targeting the cholinergic system, amyloid-β aggregation and Ca2+dyshomeostasis

Current Medicinal Chemistry

Volumn 18, Issue 4, 2011, Pages 552-576

  Leon R ^a,b,c   Marco Contelles, J ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

1,4 dihydropyridines; AChE inhibition; AChE peripheral anionic site; Alzheimer's disease; Amyloid ; Multitarget drugs; Neuroprotection; Oxidative stress; Voltage dependent calcium channels

Indexed keywords

AMYLOID BETA PROTEIN; BENZO[B][1,8]NAPHTHYRIDINE; CALCIUM; FURANOTACRINE; FURO[2,3 B]PYRIDINE; NIFEDIPINE; NIMODIPINE; PYRANOTACRINE; PYRIDINE DERIVATIVE; TACRINE; TACRINE DERIVATIVE; TACRIPYRIMIDONE; TACRIPYRINE; THIENO[2,3 B]PYRIDINE; THIOPHENOTACRINE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; ARTICLE; CALCIUM HOMEOSTASIS; CELL DEATH; CELL SURVIVAL; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; DISEASE COURSE; DRUG ACTIVITY; DRUG BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE; IC 50; NEUROPROTECTION; OXIDATIVE STRESS; PALLIATIVE THERAPY; PRESCRIPTION; PROTEIN AGGREGATION;

EID: 79851474017     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480186     Document Type: Article

References (113)

1. Alzeimer's disease international. World Alzheimer Report 2009. http://www.alz.co.uk/research/files/World%20Alzheimer%20Repo rt.pdf (April 15, 2010)
2. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P. R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503), 2112-2117. (Pubitemid 41797645)
3. Vinters, H. V. Cerebral amyloid angiopathy. A critical review. Stroke, 1987, 18(2), 311-324.
4. Lee, V. M.; Goedert, M.; Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 2001, 24, 1121-1159. (Pubitemid 32695256)
5. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y. C.; Quinlan, M.; Wisniewski, H. M.; Binder, L. I. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A., 1986, 83(13), 4913-4917.
6. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y. C.; Zaidi, M. S.; Wisniewski, H. M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem., 1986, 261(13), 6084-6089. (Pubitemid 17207447)
7. Francis, P. T.; Palmer, A. M.; Snape, M.; Wilcock, G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66(2), 137-147. (Pubitemid 29103513)
8. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356. (Pubitemid 34790756)
9. Alonso, A. C.; Grundke-Iqbal, I.; Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med., 1996, 2(7), 783-787. (Pubitemid 26225094)
10. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., 2006(1), CD005593.
11. van Marum, R. J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol., 2008, 22(3), 265-274. (Pubitemid 351712889)
12. Iqbal, K.; Grundke-Iqbal, I. Alzheimer disease is multifactorial and heterogeneous. Neurobiol. Aging, 2000, 21(6), 901-902; discussion 903-904.
13. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16(4), 881-891. (Pubitemid 26124065)
14. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol., 2001, 65(4), 391-426. (Pubitemid 32781670)
15. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Small, G. W.; Roses, A. D.; Haines, J. L.; Pericak-Vance, M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261(5123), 921-923. (Pubitemid 23275809)
16. Tiraboschi, P.; Hansen, L. A.; Masliah, E.; Alford, M.; Thal, L. J.; Corey-Bloom, J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology, 2004, 62(11), 1977-1983. (Pubitemid 38738207)
17. Ye, S.; Huang, Y.; Mullendorff, K.; Dong, L.; Giedt, G.; Meng, E. C.; Cohen, F. E.; Kuntz, I. D.; Weisgraber, K. H.; Mahley, R. W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(51), 18700-18705. (Pubitemid 43011289)
18. Bales, K. R.; Dodart, J. C.; DeMattos, R. B.; Holtzman, D. M.; Paul, S. M. Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Interv., 2002, 2(6), 363-375, 339.
19. DeMattos, R. B.; Cirrito, J. R.; Parsadanian, M.; May, P. C.; O'Dell, M. A.; Taylor, J. W.; Harmony, J. A.; Aronow, B. J.; Bales, K. R.; Paul, S. M.; Holtzman, D. M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron, 2004, 41(2), 193-202. (Pubitemid 38125181)
20. Fagan, A. M.; Watson, M.; Parsadanian, M.; Bales, K. R.; Paul, S. M.; Holtzman, D. M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis., 2002, 9(3), 305-318. (Pubitemid 34442079)
21. Brecht, W. J.; Harris, F. M.; Chang, S.; Tesseur, I.; Yu, G. Q.; Xu, Q.; Dee Fish, J.; Wyss-Coray, T.; Buttini, M.; Mucke, L.; Mahley, R. W.; Huang, Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci., 2004, 24(10), 2527-2534. (Pubitemid 38327965)
22. Harris, F. M.; Brecht, W. J.; Xu, Q.; Tesseur, I.; Kekonius, L.; Wyss-Coray, T.; Fish, J. D.; Masliah, E.; Hopkins, P. C.; Scearce-Levie, K.; Weisgraber, K. H.; Mucke, L.; Mahley, R. W.; Huang, Y. Carboxyl-terminal- truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(19), 10966-10971. (Pubitemid 37140136)
23. Huang, Y.; Liu, X. Q.; Wyss-Coray, T.; Brecht, W. J.; Sanan, D. A.; Mahley, R. W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(15), 8838-8843. (Pubitemid 32678114)
24. Lovestone, S.; Hartley, C. L.; Pearce, J.; Anderton, B. H. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience, 1996, 73(4), 1145-1157. (Pubitemid 26194338)
25. Cedazo-Minguez, A.; Popescu, B. O.; Blanco-Millan, J. M.; Akterin, S.; Pei, J. J.; Winblad, B.; Cowburn, R. F. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J. Neurochem., 2003, 87(5), 1152-1164. (Pubitemid 37492856)
26. Takashima, A.; Noguchi, K.; Sato, K.; Hoshino, T.; Imahori, K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(16), 7789-7793. (Pubitemid 23250036)
27. Takashima, A.; Noguchi, K.; Michel, G.; Mercken, M.; Hoshi, M.; Ishiguro, K.; Imahori, K. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett., 1996, 203(1), 33-36.
28. Takashima, A.; Honda, T.; Yasutake, K.; Michel, G.; Murayama, O.; Murayama, M.; Ishiguro, K.; Yamaguchi, H. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res., 1998, 31(4), 317-323. (Pubitemid 28446014)
29. Ferreira, A.; Lu, Q.; Orecchio, L.; Kosik, K. S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell Neurosci., 1997, 9(3), 220-234. (Pubitemid 27323434)
30. Lee, M. S.; Kao, S. C.; Lemere, C. A.; Xia, W.; Tseng, H. C.; Zhou, Y.; Neve, R.; Ahlijanian, M. K.; Tsai, L. H. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol., 2003, 163(1), 83-95. (Pubitemid 37271436)
31. Otth, C.; Concha, II; Arendt, T.; Stieler, J.; Schliebs, R.; Gonzalez-Billault, C.; Maccioni, R. B. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis., 2002, 4(5), 417-430. (Pubitemid 35397807)
32. Lee, M. S.; Kwon, Y. T.; Li, M.; Peng, J.; Friedlander, R. M.; Tsai, L. H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature, 2000, 405(6784), 360-364. (Pubitemid 30337070)
33. Marx, J. Alzheimer's disease. Fresh evidence points to an old suspect: calcium. Science., 2007, 318(5849), 384-385. (Pubitemid 47614497)
34. Green, K. N.; LaFerla, F. M. Linking calcium to Abeta and Alzheimer's disease. Neuron, 2008, 59(2), 190-194. (Pubitemid 352033693)
35. Khachaturian, Z. S. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann. N. Y. Acad. Sci., 1989, 568, 1-4. (Pubitemid 20166513)
36. Khachaturian, Z. S. Calcium hypothesis of Alzheimer's disease and brain aging. Ann. N. Y. Acad. Sci., 1994, 747, 1-11.
37. Pollard, H. B.; Rojas, E.; Arispe, N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann. N. Y. Acad. Sci., 1993, 695, 165-168. (Pubitemid 23348255)
38. Gandy, S.; Doeven, M. K.; Poolman, B. Alzheimer disease: presenilin springs a leak. Nat. Med., 2006, 12(10), 1121-1123. (Pubitemid 44527341)
39. Arispe, N.; Rojas, E.; Pollard, H. B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(2), 567-571. (Pubitemid 23028904)
40. Li, S.; Hong, S.; Shepardson, N. E.; Walsh, D. M.; Shankar, G. M.; Selkoe, D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 2009, 62(6), 788-801.
41. Parsons, C. G.; Stoffler, A.; Danysz, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology, 2007, 53(6), 699-723. (Pubitemid 47532143)
42. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J. Med. Chem., 2008, 51(15), 4381-4384.
43. Patrick, G. N.; Zukerberg, L.; Nikolic, M.; de la Monte, S.; Dikkes, P.; Tsai, L. H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, 1999, 402(6762), 615-622. (Pubitemid 129516324)
44. Nixon, R. A. The calpains in aging and aging-related diseases. Ageing Res. Rev., 2003, 2(4), 407-418. (Pubitemid 37159401)
45. Wen, Y.; Yu, W. H.; Maloney, B.; Bailey, J.; Ma, J.; Marie, I.; Maurin, T.; Wang, L.; Figueroa, H.; Herman, M.; Krishnamurthy, P.; Liu, L.; Planel, E.; Lau, L. F.; Lahiri, D. K.; Duff, K. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron, 2008, 57(5), 680-690. (Pubitemid 351335351)
46. Alvarez, A.; Toro, R.; Caceres, A.; Maccioni, R. B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloidinduced neuronal death. FEBS Lett., 1999, 459(3), 421-426. (Pubitemid 29467380)
47. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423(6938), 435-439. (Pubitemid 36626994)
48. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372. (Pubitemid 351252260)
49. Decker, M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev. Med. Chem., 2007, 7(3), 221-229. (Pubitemid 46488246)
50. Van der Schyf, C. J.; Geldenhuys, W. J.; Youdim, M. B. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem., 2006, 99(4), 1033-1048. (Pubitemid 44655271)
51. Youdim, M. B.; Buccafusco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26(1), 27-35. (Pubitemid 40052707)
52. Zhang, H. Y. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett., 2005, 579(24), 5260-5264.
53. Youdim, M. B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr. Alzheimer Res., 2006, 3(5), 541-550. (Pubitemid 46066429)
54. Van der Schyf, C. J.; Gal, S.; Geldenhuys, W. J.; Youdim, M. B. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin. Investig. Drugs, 2006, 15(8), 873-886. (Pubitemid 44177841)
55. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino) methyl]phenyl}-6, 7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J. Med. Chem., 2007, 50(17), 4250-4254. (Pubitemid 47301756)
56. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem. Int. Ed. Engl., 2007, 46(20), 3689-3692. (Pubitemid 46981250)
57. Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem., 2007, 50(20), 4882-4897. (Pubitemid 47525472)
58. Kogen, H.; Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Org. Lett., 2002, 4(20), 3359-3362.
59. Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini Rev. Med. Chem., 2006, 6(11), 1269-1274. (Pubitemid 44697107)
60. Zheng, H.; Youdim, M. B.; Fridkin, M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotectiveneurorestorative moieties for Alzheimer's therapy. J. Med. Chem., 2009, 52(14), 4095-4098.
61. Mattson, M. P.; Chan, S. L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci., 2001, 17(2), 205-224. (Pubitemid 33063525)
62. Knapp, M. J.; Knopman, D. S.; Solomon, P. R.; Pendlebury, W. W.; Davis, C. S.; Gracon, S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA, 1994, 271(13), 985-991. (Pubitemid 24099918)
63. Walgren, J. L.; Mitchell, M. D.; Thompson, D. C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 2005, 35(4), 325-361. (Pubitemid 40691298)
64. Martinez-Grau, A.; Marco, J. L. Friedlander reaction on 2-amino-3-cyano-4H-pyrans: Synthesis of derivatives of 4H-pyran[2, 3-b] quinoline, new tacrine analogues. Bioorg. Med. Chem. Lett., 1997, 7(24), 3165-3170. (Pubitemid 28009340)
65. Marco, J. L.; de los Rios, C.; Carreiras, M. C.; Banos, J. E.; Badia, A.; Vivas, N. M. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues. Bioorg. Med. Chem., 2001, 9(3), 727-732. (Pubitemid 32208592)
66. de los Rios, C.; Marco, J. L.; Carreiras, M. D.; Chinchon, P. M.; Garcia, A. G.; Villarroya, M. Novel tacrine derivatives that block neuronal calcium channels. Bioorg. Med. Chem., 2002, 10(6), 2077-2088. (Pubitemid 34286399)
67. Marco, J. L.; De los Rios, C.; Carreiras, M. C.; Banos, J. E.; Badia, A.; Vivas, N. M. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of 4-amino-2, 3-diaryl-5, 6, 7, 8-tetrahydrofuro (and thieno) [2, 3-b]-quinolines, and 4-amino-5, 6, 7, 8, 9-pentahydro-2, 3-diphenylcyclohepta [e]furo (and thieno)-[2, 3-b]pyridines. Arch. Pharm. (Weinheim), 2002, 335(7), 347-353.
68. Marco, J. L.; de los Rios, C.; Garcia, A. G.; Villarroya, M.; Carreiras, M. C.; Martins, C.; Eleuterio, A.; Morreale, A.; Orozco, M.; Luque, F. J. Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/ butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors. Bioorg. Med. Chem., 2004, 12(9), 2199-2218. (Pubitemid 38471708)
69. Orozco, C.; de los Rios, C.; Arias, E.; Leon, R.; Garcia, A. G.; Marco, J. L.; Villarroya, M.; Lopez, M. G. ITH4012 (ethyl 5-amino-6, 7, 8, 9-tetrahydro-2-methyl-4-phenylbenzol [1, 8]naphthyridine-3-car boxylate), a novel acetylcholinesterase inhibitor with "calcium promotor" and neuroprotective properties. J. Pharmacol. Exp. Ther., 2004, 310(3), 987-994. (Pubitemid 39108919)
70. Marco-Contelles, J.; León, R.; Morales, E.; Villarroya, M.; García, A. G. Synthesis, electrochemical and biological studies on polyfunctionalized 4-ferrocenyl-1, 4-dihydropyridine derivates. Tetrahedron Lett., 2004, 45, 5203-5205. (Pubitemid 38757471)
71. Leon, R.; Marco-Contelles, J.; Garcia, A. G.; Villarroya, M. Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues. Bioorg. Med. Chem., 2005, 13(4), 1167-1175. (Pubitemid 40173925)
72. Marco-Contelles, J.; Leon, R.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Synthesis and biological evaluation of new 4H-pyrano [2, 3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause neuroprotection against calcium overload and free radicals. Eur. J. Med. Chem., 2006, 41(12), 1464-1469. (Pubitemid 44880506)
73. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Garcia, A. G.; Lopez, M. G.; Villarroya, M. New multipotent tetracyclic tacrines with neuroprotective activity. Bioorg. Med. Chem., 2006, 14(24), 8176-8185. (Pubitemid 44667565)
74. Leon, R.; Garcia, A. G.; Marco-Contelles, J. Unexpected results in the Friedländer reaction of 4-aryl-7, 7-dimethyl-5-oxo-5, 6, 7, 8-tetrahydro-4H-[1]bezopyran-3-carbonitriles. J. Chem. Res., 2006, 8, 536-538. (Pubitemid 44421863)
75. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Guglietta, A.; Terencio, J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 2006, 49(26), 7607-7610. (Pubitemid 46033653)
76. Leon, R.; de los Rios, C.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Luque, F. J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Med. Chem., 2008, 16(16), 7759-7769.
77. Leon, R.; de los Rios, C.; Marco-Contelles, J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Synthesis of 6-amino-1, 4-dihydropyridines that prevent calcium overload and neuronal death. Eur. J. Med. Chem., 2008, 43(3), 668-674. (Pubitemid 351323999)
78. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodriguez-Franco, M. I.; Lopez, B.; Lopez, M. G.; Garcia, A. G.; Carreiras Mdo, C.; Villarroya, M. Tacripyrines, the first tacrinedihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52(9), 2724-2732.
79. Rappaport, F.; Fischl, J.; Pinto, N. An improved method for the estimation of cholinesterase activity in serum. Clin. Chim. Acta., 1959, 4(2), 227-230.
80. Radic, Z.; Reiner, E.; Taylor, P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol. Pharmacol., 1991, 39(1), 98-104.
81. Schanne, F. A.; Kane, A. B.; Young, E. E.; Farber, J. L. Calcium dependence of toxic cell death: a final common pathway. Science, 1979, 206(4419), 700-702. (Pubitemid 10203221)
82. Patterson, P. H. Control of cell fate in a vertebrate neurogenic lineage. Cell, 1990, 62(6), 1035-1038.
83. Garcia, A. G.; Garcia-De-Diego, A. M.; Gandia, L.; Borges, R.; Garcia-Sancho, J. Calcium signaling and exocytosis in adrenal chromaffin cells. Physiol. Rev., 2006, 86(4), 1093-1131. (Pubitemid 44523705)
84. 2+ channel components of Ba2+ currents in bovine chromaffin cells superfused with solutions containing low and high Ba2+ concentrations. Pflugers Arch., 1996, 432(6), 1030-1038. (Pubitemid 26338691)
85. 2+. Methods Mol. Biol., 2006, 312, 135-145.
86. Garcia, A. G.; Albillos, A.; Cano-Abad, M. F.; Garcia-Palomero, E.; Hernandez-Guijo, M.; Herrero, C. J.; Lomax, R. B.; Gandia, L. Calcium channels for exocytosis in chromaffin cells. Adv. Pharmacol., 1998, 42, 91-94.
87. Cano-Abad, M. F.; Villarroya, M.; Garcia, A. G.; Gabilan, N. H.; Lopez, M. G. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem., 2001, 276(43), 39695-39704.
88. 2+ channels in rat aorta smooth muscle cells in primary culture. Circ. Res., 1990, 67(2), 469-480. (Pubitemid 20242588)
89. Sultana, R.; Butterfield, D. A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis., 2010, 19(1), 341-353.
90. Shutske, G. M.; Kapples, K. J. Preparation of fused heterocyclic aminotetrahydroquinolinols and related compounds as memory enhancers. US Patent, 1988, 4753950.
91. Desai, M. C. Tricyclic 4-aminopyridine derivatives for treatment of Alzheimer's disease, and their pharmaceutical compositions, preparation, and intermediates. Eur. Patent, 1989, 311303.
92. Chaki, H.; Yamabe, H.; Sugano, M.; Morita, S.; Bessho, T.; Tabata, R.; Saito, K. I.; Egawa, M.; Tobe, A.; Morinaka, Y. Design and syntheses of 4-acylaminopyridine derivatives - novel highaffinity choline uptake enhancers.2. Bioorg. Med. Chem. Lett., 1995, 5(14), 1495-1500.
93. Gewald, K. Heterocyclen aus ch-aciden nitrilen. 9. Uber die reaktion von alpha-hydroxy-ketonen mit malodinitril. Chem. Ber.-Recl., 1966, 99(3), 1002-&.
94. Feng, X.; Lancelot, J. C.; Prunier, H.; Rault, S. First synthesis of 4H-furo [3, 2-f]pyrrolo [1, 2-alpha] [1, 4]diazepines. J. Heterocycl. Chem., 1996, 33(6), 2007-2011.
95. Ellman, G. L.; Courtney, K. D.; Andres, V. Jr.; Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
96. Tu, S.; Zhang, J.; Zhu, X.; Wang, Q.; Xu, J.; Jiang, B.; Jia, R.; Zhang, J.; Shi, F. One-pot synthesis of hexahydroquinolines via. a four-component cyclocondensation under microwave irradiation in solvent free conditions: a green chemistry strategy. J. Heterocycl. Chem., 2006, 43, 985.
97. Chatonnet, A.; Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J., 1989, 260(3), 625-634. (Pubitemid 19155655)
98. Inestrosa, N. C.; Alvarez, A.; Calderon, F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid betapeptide into Alzheimer's filaments. Mol. Psychiatry, 1996, 1(5), 359-361.
99. Troschutz, R. [Synthesis of pyrido [2, 3-d]pyrimidines with a trimethoprim partial structure. Arch. Pharm. (Weinheim), 1989, 5, 285-290. (Pubitemid 19127594)
100. Cheng, C. C. The Friedländer synthesis of quinolines. Org. React., 1982, 28, 37-201.
101. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl (methyl) amino]methyl]phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem., 2003, 46(12), 2279-2282. (Pubitemid 36637912)
102. Bartolini, M.; Bertucci, C.; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C.; Andrisano, V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem, 2007, 8(17), 2152-2161. (Pubitemid 350220767)
103. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multitarget-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6(1), 152-162.
104. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65(3), 407-416. (Pubitemid 36084557)
105. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med., 2010, 362(4), 329-344.
106. Mattson, M. P.; Chan, S. L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 2003, 34 (4-5), 385-397. (Pubitemid 37021231)
107. Le, Y.; Gong, W.; Tiffany, H. L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N. M.; Gao, J. L.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. Amyloid (beta) 42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci., 2001, 21(2), RC123.
108. Sapra, M.; Kim, K. Y. Anti-amyloid treatments in Alzheimer's disease. Recent. Pat. CNS. Drug. Discov., 2009, 4(2), 143-148.
109. Kawahara, M.; Negishi-Kato, M.; Sadakane, Y. Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein. Expert Rev. Neurother., 2009, 9(5), 681-693.
110. Scott, L. E.; Orvig, C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem. Rev., 2009, 109(10), 4885-4910.
111. Ferrari, D.; Yang, L. H.; Miles, E. W.; Dunn, M. F. Beta D305A mutant of tryptophan synthase shows strongly perturbed allosteric regulation and substrate specificity. Biochemistry, 2001, 40(25), 7421-7432. (Pubitemid 32578006)
112. Andersen, J. K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med., 2004, 10 (Suppl), S18-25. (Pubitemid 38901863)
113. Aliev, G.; Palacios, H. H.; Walrafen, B.; Lipsitt, A. E.; Obrenovich, M. E.; Morales, L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int. J. Biochem. Cell Biol., 2009, 41(10), 1989-2004.